Jazz Pharmaceuticals (JAZZ) posted Q1 non-GAAP earnings late Tuesday of $1.68 per diluted share, down from $2.63 a year ago.

Analysts polled by FactSet expected $4.66.

Revenue for the quarter ended March 31 was $897.8 million, down from $902.0 million a year earlier.

Analysts surveyed by FactSet expected $983.8 million.

For 2025, the company said it now expects adjusted EPS of $4.00 to $5.60 on revenue of $4.15 billion to $4.40 billion.

It forecast EPS of $22.50 to $24.00 previously. Analysts expected $23.22 and $4.29 billion, respectively.

Shares of Jazz were down about 6.5% in after-hours activity.